Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study

Brian A. Jonas; Courtney DiNardo; Nicola Fracchiolla; Alexander Pristupa; Kenichi Ishizawa; Jie Jin; Marina Konopleva; Yishai Ofran; Pau Montesinos; Tibor Kovacsovics; Jun Ho Jang; Hagop Kantarjian; Yinghui Duan; Jalaja Potluri; Michael Werner; Keith W. Pratz

doi:10.1002/ajh.26707

Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study

Brian A. Jonas
, Courtney DiNardo
, Nicola Fracchiolla
, Alexander Pristupa
, Kenichi Ishizawa
, Jie Jin
, Marina Konopleva
, Yishai Ofran
, Pau Montesinos
, Tibor Kovacsovics
, Jun Ho Jang
, Hagop Kantarjian
, Yinghui Duan
, Jalaja Potluri
, Michael Werner
, Keith W. Pratz

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Original language	English
Pages (from-to)	E422-E425
Journal	American Journal of Hematology
Volume	97
Issue number	11
DOIs	https://doi.org/10.1002/ajh.26707
State	Published - Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ajh.26707

Cite this

Jonas, B. A., DiNardo, C., Fracchiolla, N., Pristupa, A., Ishizawa, K., Jin, J., Konopleva, M., Ofran, Y., Montesinos, P., Kovacsovics, T., Jang, J. H., Kantarjian, H., Duan, Y., Potluri, J., Werner, M., & Pratz, K. W. (2022). Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. American Journal of Hematology, 97(11), E422-E425. https://doi.org/10.1002/ajh.26707

@article{49fec9c22fda499284c89341f5ee66e4,

title = "Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study",

author = "Jonas, \{Brian A.\} and Courtney DiNardo and Nicola Fracchiolla and Alexander Pristupa and Kenichi Ishizawa and Jie Jin and Marina Konopleva and Yishai Ofran and Pau Montesinos and Tibor Kovacsovics and Jang, \{Jun Ho\} and Hagop Kantarjian and Yinghui Duan and Jalaja Potluri and Michael Werner and Pratz, \{Keith W.\}",

year = "2022",

month = nov,

doi = "10.1002/ajh.26707",

language = "English",

volume = "97",

pages = "E422--E425",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc",

number = "11",

}

Jonas, BA, DiNardo, C, Fracchiolla, N, Pristupa, A, Ishizawa, K, Jin, J, Konopleva, M, Ofran, Y, Montesinos, P, Kovacsovics, T, Jang, JH, Kantarjian, H, Duan, Y, Potluri, J, Werner, M & Pratz, KW 2022, 'Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study', American Journal of Hematology, vol. 97, no. 11, pp. E422-E425. https://doi.org/10.1002/ajh.26707

TY - JOUR

T1 - Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study

AU - Jonas, Brian A.

AU - DiNardo, Courtney

AU - Fracchiolla, Nicola

AU - Pristupa, Alexander

AU - Ishizawa, Kenichi

AU - Jin, Jie

AU - Konopleva, Marina

AU - Ofran, Yishai

AU - Montesinos, Pau

AU - Kovacsovics, Tibor

AU - Jang, Jun Ho

AU - Kantarjian, Hagop

AU - Duan, Yinghui

AU - Potluri, Jalaja

AU - Werner, Michael

AU - Pratz, Keith W.

PY - 2022/11

Y1 - 2022/11

UR - https://www.scopus.com/pages/publications/85138190135

U2 - 10.1002/ajh.26707

DO - 10.1002/ajh.26707

M3 - Article

C2 - 36053878

AN - SCOPUS:85138190135

SN - 0361-8609

VL - 97

SP - E422-E425

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 11

ER -

Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study

UN SDGs

Access to Document

Other files and links

Cite this